Molecular docking studies of potent inhibitors of tyrosinase and α-glucosidase

Medicinal Chemistry Research

Volumn 21, Issue 8, 2012, Pages 1677-1683

  Azam, Syed Sikander ^a   Uddin, Reaz ^b   Syed, Adnan Ali Shah ^c   Zaheer Ul Haq, ^b  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Alpha glucosidase; Binding sites; Inhibitors; Ligand interaction; Molecular docking; Tyrosinase

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; COPPER; METAL ION; MONOPHENOL MONOOXYGENASE; OXYGENASE INHIBITOR; TIBOLONE; TYROSINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL PARAMETERS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME METABOLISM; GLYCEMIC CONTROL; METABOLITE; MOLECULAR DOCKING;

EID: 84866109606     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9684-3     Document Type: Article

References (36)

1. Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPAinduced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5:165-176
2. Azam SS, Hofer TS, Randolf BR, Rode BM (2009a) Hydration of sodium(I) and potassium(I) revisited: a comparative QM/MM and QMCF MD simulation study of weakly hydrated ions. J Phys Chem A 113:1827-1834
3. Azam SS, Hofer TS, Randolf BR, Rode BM (2009b) Germinum(II) in water: an unsual hydration structure results of a QMCF MD simulation. Chem Phys Lett 470:85-89
4. Azam SS, Hofer TS, Bhattacharjee A, Lim LHV, Pribil AB, Randolf BR, Rode BM (2009c) Beryllium(II): The Strongest Structure-Forming Ion in Water? A QMCF MD simulation study. J Phys Chem B 113(27):9289-9295
5. Azam SS, Lim LHV, Hofer TS, Randolf BR, Rode BM (2010) Hydrated germanium(II): irregular structural and dynamical properties revealed by a quantum mechanical charge field molecular dynamics study. J Comput Chem 31(2):278-285
6. Barroso, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GLI, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O'Rahilly S (1999) Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242
8. Bissantz C, Folkers G, Rognan D (2000) Protein-based virtual screening of chemical database. 1. Evaluation of different docking/scoring combinations. J Med Chem 43:4759-4765
9. Choudhary MI, Shah SAA, Rehman A, Khan SN, Khan MTH (2010) Alpha-glucosidase and tyrosinase inhibitors form fungal hydroxylation of tibolone and hydroxytibolones. Steroids 75(12):956-966
10. GOLD (2005) GOLD version 3.2. Cambridge Crystallographic Data Centre, Cambridge
11. Heightman TD, Vasella AT (1999) Recent insights into inhibition, structure and mechanism of configuration-retaining glycosidases. Angew Chem Int Ed 38:750-770
12. Hong L, XunM,WutongW(2007) Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice. J Pharm Pharmacol 59(4):575-582
13. Horio H, Ohtsuru M (2001) Maitake (Grifola frondosa) improve glucose tolerance of experimental diabetic rats. J Nutr Sci Vitaminol (Tokyo) 47(1):57-63
14. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748
15. Khatib S, Nerya O, Musa R, Shumuel M, Tamir S, Vaya J (2005) Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety. Bio Med Chem 13:433-441
16. Kim YJ, Uyama H (2005) Tyrosinase inhibitors form natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cellular Mol Life Sci 62(15):1707-1723
17. Kimura A, Lee JH, Lee IS, Lee HS, Park KH, Chiba S, Kim D (2004) Two potent competitive inhibitors discriminating alpha-glucosidase family I from family II. Carbohydr Res 339:1035-1040
18. Konno S, Tortorelis DG, Fullerton SA, Samadi AA, Hettiarachchi J, Tazaki H (2001) A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients. Diabet Med 18(12):1010
19. Kubo K, Aoki H, Nanba H (1994) Anti-diabetic activity present in the fruit body of Grifola frondosa (Maitake) I. Biol Pharm Bull 17(8):1106-1110
20. Lo HC, Hsu TH, Chen CY (2008) Submerged culture mycelium and broth of Grifola frondosa improve glycemic responses in diabetic rats. Am J Chin Med 36(2):265-285
21. Manohar V, Talpur NA, Echard BW, Lieberman S, Preuss HG (2002) Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. Diabetes Obes Metab 4(1):43-48
22. Matsuo T, Odaka H, Ikeda H (1992) Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 55(1 Suppl):314S-317S
23. Molecular Operating Environment (2008) Molecular Operating Environment MOE: Version 2008.10. C. C. G. I. M, Quebec
24. Nissink JW, Murray C, Hartshorn M, Verdonk ML, Cole JC (2002) A new test set for validating predictions of protein-ligand interaction. Proteins 4:457-471
25. Oetting WS (2000) The tyrosinase gene and oculocutaneous albinism type 1 (OCA1): a model for understanding the molecular biology of melanin formation. Pigment Cell Res 13:320-325
26. Parvaiz S, Kang M, Chung HS, Bae H (2007) Naturally occurring tyrosinase inhibitors: mechanism and applications in skin health cosmetics and agriculture industries. Phytotherapy Res 21:805-816
27. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612
28. Prezioso JA, Epperly MW, Wang N, Bloomer WD (1992) Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S- cysteaminylphenol in melanoma cells. Cancer Lett 63:73-79
29. Priestly GC (1993) Molecular aspects of dermatology. John Wiley, Chichester
30. Sanchez-Ferrer A, Rodriguez-Loez JN, Garcia-Canovas F, Garcia-Carmona F (1995) Tyrosinase: a comprehensive review of its mechanism. Biochem Biophys Acta 1247(1):1-11
31. Scheen AJ (2003) Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 63:933-951
32. Sudhir R, Mohan V (2002) Postprandial hyperglycemia in patients with type 2 diabetes mellitus. Treat Endocrinol 1:105-116
33. Toledo-Sherman LM, Chem D (2002) High-throughput screening for drug discovery in parallel. Curr Opin Drug Discovery Dev 5(3):414-421
34. Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, De Grauw WJC (2006) Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev. CD005061. doi: 10.1002/14651858.CD005061.pub2
35. Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE (1997) Tyrosinase mRNA is expressed in human substantia nigra. Mol Brain Res 45(1):159-162
36. Xu Y, Stokes AH, Roskoski RJ, Vrana KE (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54:691-697